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Impaired HDL Function Amplifies 
Systemic Inflammation in Common 
Variable Immunodeficiency
Magnhild e. Macpherson1,2,3, Bente Halvorsen1,3, Arne Yndestad1, Thor Ueland1,3,8, 
tom e. Mollnes6,7,8,9, Rolf K. Berge4,5, Azita Rashidi1, Kari otterdal1, Ida Gregersen1,3, 
Xiang Y. Kong1,3, Kirsten B. Holven10,11, Pål Aukrust1,2,3,8, Børre Fevang1,2 & silje F. Jørgensen1,2,3
Common variable immunodeficiency (CVID) is the most common symptomatic primary 
immunodeficiency, characterized by inadequate antibody responses and recurrent bacterial infections. 
Paradoxically, a majority of CVID patients have non-infectious inflammatory and autoimmune 
complications, associated with systemic immune activation. Our aim was to explore if HDL, known to 
have anti-inflammatory properties, had impaired function in CVID patients and thereby contributed 
to their inflammatory phenotype. We found reduced HDL cholesterol levels in plasma of CVID 
patients compared to healthy controls, particularly in patients with inflammatory and autoimmune 
complications, correlating negatively with inflammatory markers CRP and sCD25. Reverse cholesterol 
transport capacity testing showed reduced serum acceptance capacity for cholesterol in CVID 
patients with inflammatory and autoimmune complications. They also had reduced cholesterol efflux 
capacity from macrophages to serum and decreased expression of ATP-binding cassette transporter 
ABCA1. Human HDL suppressed TLR2-induced TNF release less in blood mononuclear cells from CVID 
patients, associated with decreased expression of transcriptional factor ATF3. Our data suggest a link 
between impaired HDL function and systemic inflammation in CVID patients, particularly in those with 
autoimmune and inflammatory complications. This identifies HDL as a novel therapeutic target in CVID 
as well as other more common conditions characterized by sterile inflammation or autoimmunity.
Common variable immunodeficiency (CVID) is a heterogeneous disease where the immune system fails to pro-
duce sufficient amounts of antibodies, resulting in reduced levels of immunoglobulin (Ig)G, IgM and/or IgA. It 
is the most common symptomatic primary immunodeficiency in adults with a prevalence of 1:25 000–1:50 000 
in Caucasians1. Monogenic causes are identified in approximately 10–20% of CVID patients2–4, but in most cases 
the etiology is unknown though might include polygenic variations in addition to epigenetic modifications5,6. 
The clinical hallmark of CVID is increased susceptibility to respiratory tract infections with encapsulated bac-
teria. Paradoxically, a large proportion of CVID patients also have autoimmune and non-infectious inflamma-
tory complications such as lymphoid hyperplasia, granuloma, lymphoid interstitial pneumonitis, gastrointestinal 
inflammation and a variety of autoimmune disorders7. In line with this, CVID patients show signs of persistent 
systemic inflammation including monocyte/macrophage and T-cell activation, with increased levels of inflamma-
tory mediators such as C-reactive protein (CRP), tumor necrosis factor (TNF), soluble (s) CD25 and sCD148–11.
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In view of the wide variety of phenotypes in CVID, it is useful to subdivide the patient group into two main 
categories: those with infections only and those who also display non-infectious complications. Importantly, 
CVID patients with one or more of these non-infectious complications have an 11-fold increase in mortality7. 
Whereas IgG replacement therapy reduces the severity and frequency of infections, it has little effect on the 
inflammatory and autoimmune complications12. It is therefore of major importance to elucidate the mechanisms 
of these non-infectious complications in order to identify new targets for therapy in CVID13.
The anti-inflammatory properties of high-density lipoprotein (HDL) are well established in atherosclerotic 
disorders, but have also been suggested in non-atherosclerotic conditions such as sepsis, autoimmune disorders 
and cancer14–16. In vitro and in vivo experiments have suggested an anti-inflammatory role for HDL by its ability 
to counteract toll-like receptor (TLR)-induced inflammation in macrophages via activating transcription factor 
3 (AFT3)17. Decreased cholesterol efflux capacity from peripheral cells, which is influenced by HDL activity, has 
in murine models of dendritic cells been shown to result in autoimmunity and inflammation via increased intra-
cellular inflammasome activity18.
Based on the above, we hypothesized HDL levels and functional activity to be altered in CVID, possibly con-
tributing to systemic immune activation and inflammation as well as development of autoimmunity. We explored 
this hypothesis both by conducting analyses of lipid profiles in a large CVID population and by running experi-
mental studies of HDL function in relation to cholesterol efflux capacity and anti-inflammatory effects in CVID 
patients and controls. Here, we present novel insights into the role of HDL in systemic inflammation of CVID, 
findings that can be of relevance to other autoimmune and inflammatory disorders as well.
Results
Patients’ characteristics. Clinical characteristics of the 102 CVID patients included in the lipid- and inflamma-
tory analyses are shown in Table 1. In addition, a complete description of their autoimmune and inflammatory compli-
cations is given in Supplemental Table S1. Not all sub analyses and in vitro experiments were performed in all patients 
and so clinical characteristics of the 40 patients making up the smaller cohort, used for HDL subclass analyses and 
PBMC gene expression studies, and also the cohorts used for functional studies are shown in Supplemental Table S2. 
A complete overview of the CVID patients participating in the different analyses is given in Supplemental Table S3.
The CVID patients had decreased HDL cholesterol levels. We measured the total cholesterol, HDL 
cholesterol and LDL cholesterol levels in plasma from 102 CVID patients and 28 healthy controls. Compared to 
healthy controls, CVID patients had lower plasma HDL levels (1.66 [1.42, 1.84] vs 1.16 [0.91, 1.55], p < 0.0001, 
median [25th, 75th percentile] mmol/L, respectively) (Fig. 1), whilst LDL (p = 0.99) and total cholesterol levels 
(p = 0.57) showed no significant difference. Low HDL levels in CVID patients compared to controls were consist-
ent after correcting for sex, BMI and age (p < 0.001).
In 32 of the CVID patients we had two HDL measurements (mean time gap between sample collection 21 
months, range 8–28 months) and found no significant difference between HDL levels measured at the two dif-
ferent time points (p = 0.42), suggesting that decreased HDL levels is a stable feature in CVID (Supplemental 
Fig. S1).
Out of 102 CVID patients, seven (7%) were using statins and 18 (18%) had a disease history of cardiovascu-
lar disease (defined as hypertension requiring medical treatment [n = 16] or coronary artery disease [n = 2]). 
Importantly, HDL cholesterol levels in these patients did not differ from the other CVID patients (1.12 ± 0.13 in 
statin users vs 1.26 ± 0.04 in non-statin users; p = 0.439, and 1.15 ± 0.11 for patients with cardiovascular disease 
vs 1.28 ± 0.05 for those without cardiovascular disease; p = 0.234, HDL levels given in mean ± SEM mmol/L).
Low HDL cholesterol levels were associated with systemic inflammation and non-infectious 
complications in CVID. When dividing the CVID cohort into subgroups by phenotype, we found signifi-
cantly lower HDL levels in CVID patients with non-infectious complications (n = 76) than in CVID patients with 
infections only (n = 26) (1.1 [0.9, 1.5] vs 1.4 [1.1, 1.9] respectively, p < 0.01, HDL results given as median [25th, 
75th percentile] mmol/L) (Fig. 1). There was no significant difference between healthy controls and patients with 
infections only (p = 0.09), hence the low HDL levels in those with non-infectious complications were driving the 




(n = 28) p-value
Age in years mean ± SD [min-max] 48 ± 15 [18–83] 42 ± 10 [28–65] 0.053*
Female (%) 54% 64% 0.328†
BMI mean ± SD [min-max] 25 ± 4 [17–39] 24 ± 3 [19–34] 0.232‡
IVIG (%) 18 (18%) — —
SCIG (%) 71 (70%) — —
IVIG and SCIG’ (%) 12 (12%) — —
Infections only (%) 26 (26%) — —
Non-infectious complications (%) 76 (75%) — —
Table 1. Patient characteristics for CVID cohort and healthy controls. BMI: Body mass index. IVIG: 
Intravenous immunoglobulins. SCIG: Subcutaneous immunoglobulins. ‘One CVID patient did not receive any 
immunoglobulin substitution. *Mann Whitney test, †Pearson Chi square test, ‡Student’s t-test.
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Furthermore, we found a negative correlation between plasma levels of HDL cholesterol and sCD25 
(r = −0.59, p < 0.001) and CRP (r = −0.24, p = 0.018) (Fig. 2a,b), but not with LPS (r = −0.08, p = 0.407) or 
sCD14 (r = −0.16, p = 0.119) in CVID patients. Combined, these findings suggest that the decreased levels of 
HDL cholesterol in CVID are associated with increased systemic immune activation and an inflammatory and 
autoimmune phenotype. Stepwise regression identified sCD25 (beta = −0.52, p = 0.001) and sex (beta = −0.33, 
p = 0.034) as the strongest predictors of HDL cholesterol levels in CVID (Supplemental Table S4).
HDL subclasses and Apo A-1 in CVID. HDL particles are heterogeneous and can be fractioned into subclasses 
defined by density or size reflecting differences in relative content of proteins and lipids: small (S), medium (M), large 
(L) and extra-large (XL). Hence, the HDL subclasses vary in composition and also differ in capacity of contributing 
to reverse cholesterol transport as well as anti-oxidative and anti-inflammatory activity19. Several studies have found 
lipid-free Apo A-1 and the smaller forms of HDL to be the main acceptors of cholesterol efflux via the ATP-binding 
cassette transporter (ABCA1) pathway in macrophages20,21. We therefore next measured plasma concentration of Apo 
A-1 and each HDL subclass in 40 CVID patients and 28 healthy controls (characteristics are given in Supplemental 
Table S2). CVID patients had significantly lower levels of M-HDL (p = 0.025), L-HDL (p = 0.005) and XL-HDL 
(p = 0.041), but not S-HDL (p = 0.778) (Supplemental Fig. S2). Importantly, Apo A-1, the main protein and functional 
component of HDL19,22 was also significantly lower in our CVID patients compared to healthy controls (p = 0.005) 
(Fig. 3). Thus, although the normal proportion of S-HDL could suggest a normal reverse cholesterol transport (RCT) 
function, HDL particles in CVID had markedly reduced levels of Apo A-1, predicting impairment of function.
Serum from CVID patients had decreased cholesterol acceptor function. To further look into the 
functional capacity of HDL in CVID patients, we tested the cholesterol acceptor function of HDL in a subgroup of 
CVID patients (n = 18) and healthy controls (n = 10); characteristics are given in Supplemental Table S2. Serum was 
employed, as its cholesterol acceptance is mainly driven by HDL function and concentration. We exposed THP-1 mac-
rophages to 14C-cholesterol for  48 hours before cholesterol efflux was induced by serum from either CVID patients or 
controls. We found significantly decreased cholesterol acceptor capacity in serum from CVID patients compared to 
healthy controls (14.1% [13.0%, 15.3%] versus 15.0% [14.7%, 17.3%], p < 0.05, results given as median [25% percentile, 
75% percentile]) (Fig. 4), illuminating reduced function of a key step in RCT in these patients. Furthermore, when 
dividing the patients into the two clinical subgroups, serum from CVID patients with non-infectious complications 
had significantly reduced cholesterol acceptor capacity (13.5% [12.7%, 14.7%]) compared to controls (p = 0.003), in 
contrast with those who suffered from infections only (15.3% [13.1%, 15.6%], p = 0.46, all results given as median [25% 
percentile, 75% percentile]) (Fig. 4). These findings suggest that CVID patients with autoimmune and inflammatory 
complications have decreased HDL function and not only decreased HDL levels.
CVID patients had decreased expression of ABCA1. Reversed cholesterol transport is not only 
dependent on HDL acceptor capacity, but also the cellular transport properties of the cholesterol-loaded cells. 
Further exploring cellular transport activity, we analyzed mRNA expression of RCT related genes measured 
by qPCR on PBMC from 40 CVID patients and 30 healthy controls (characteristics are given in Supplemental 
Table S2). We found significantly lower levels of ABCA1 mRNA in CVID patients than in healthy controls 
(p < 0.0001) (Fig. 5). There was no significant difference in mRNA expression of ABCG1 (p = 0.17), SR-A1 
(p = 0.55) or SR-B1 (p = 0.32) between CVID patients and healthy controls, respectively (Fig. 5).
Figure 1. HDL cholesterol levels in CVID patients and controls including CVID subgroups. Plasma levels of 
HDL cholesterol in Common Variable Immunodeficiency (CVID) patients and controls. The CVID cohort is 
further divided into two subgroups: infection only and non-infectious complications. Results are given as boxes 
representing the 25th to 75th percentile with lines indicating median and whiskers min-max values; **p < 0.01, 
****p < 0.0001 using Mann-Whitney test between groups.
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Cholesterol efflux capacity decreased in macrophages from CVID patients. In order to fur-
ther assess reverse cholesterol transport capacity in CVID, we used monocyte derived macrophages from 11 
CVID patients and 11 age and sex matched controls (in this particular experiment only CVID patients with 
non-infectious complications were included; Supplemental Table S2) and a uniform control serum (2.5%, v/v) 
as acceptor. We exposed macrophages to 14C-cholesterol for  48 hours for cholesterol loading followed by over-
night stabilization in medium without additives before efflux was analyzed. Whereas there was no difference in 
cholesterol loading between macrophages from CVID patients and controls (data not shown), macrophages from 
Figure 2. Correlation between HDL cholesterol levels and inflammatory markers in CVID. Panels show 
correlation between HDL cholesterol and sCD25 (a) and CRP (b) in CVID patients (n = 102). Comparisons are 
made by Spearman’s rank correlation test. Spearman’s rank correlation coefficient is referred to as r. Trend lines 
indicate negative correlation between variables sCD25 and HDL cholesterol as well as between CRP and HDL 
cholesterol.
Figure 3. Apo A-1 levels in CVID patients and controls. The results are given as mean with error bars for SD. 
**p < 0.01 using unpaired Student’s t-test between groups.
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CVID patients had significantly reduced cholesterol efflux capacity as compared to macrophages from healthy 
controls (14.6% [12.2%, 18.2%] vs 16.3% [13.0%, 21.3%], p = 0.04, results given as median [25% percentile, 75% 
percentile]) (Fig. 6), consistent with our findings of low ABCA1 expression in CVID patients.
Impaired anti-inflammatory effect of HDL on TLR stimulation of PBMC from CVID patients. 
HDL has recently been shown to attenuate TLR mediated inflammatory response in macrophages as assessed 
by IL-6 and TNF measurements, at least partly mediated by the transcriptional regulator ATF317. Thus, we next 
examined the interaction between HDL and ATF3 in PBMC from CVID patients and controls. PBMC from 40 
CVID patients had decreased ATF3 mRNA levels compared to PBMC from 30 healthy controls (p < 0.0001, 
Fig. 7a) (cohort characteristics given in Supplemental Table S2). We explored this further by incubating freshly 
isolated PBMC from six CVID patients and six age and sex matched healthy controls (in this particular sub-study 
only CVID patients with an inflammatory phenotype were included; Supplemental Table S2) in the presence of 
different concentrations of human HDL for 6 hours. We then stimulated the cells with TLR4 (LPS) and TLR2 
(Pam3Cys) ligands for 12 hours, and found a suppressive effect of HDL on TNF release in Pam3Cys exposed cells 
in healthy controls (Fig. 7b). Notably, however, the suppressive effect of HDL on TNF release was significantly 
decreased in cells from CVID patients stimulated with TLR2 ligand Pam3Cys (Fig. 7b), but not with TLR4 ligand 
LPS. The same effect was not observed for IL-6 release (Supplemental Fig. S3).
Discussion
In the present study, we show decreased levels of HDL cholesterol associated with systemic inflammation and 
inflammatory and autoimmune complications in CVID. Our functional studies demonstrate impaired HDL cho-
lesterol acceptor function and impaired reverse cholesterol transport from macrophages in CVID, likely related 
to decreased levels of Apo A-1 and low mRNA expression of ABCA1 in these patients. Furthermore, our find-
ings suggest attenuated anti-inflammatory effects of HDL on PBMC from CVID patients, which could reflect 
their decreased ATF3 expression. This study proposes new pathogenic mechanisms for the clinically significant 
Figure 4. Cholesterol efflux from THP-1 macrophages to serum in CVID patients and controls. The results are 
given as median with interquartile range showing cholesterol efflux in CVID patients and healthy controls as 
well as in the CVID subgroups: infection only and non-infectious complications. *p < 0.05, **p < 0.01 using 
Mann-Whitney test between groups.
Figure 5. Reverse cholesterol transport related gene expression in PBMC from CVID patients and controls. 
mRNA expression in PBMC from CVID patients (n = 40) and healthy controls (n = 30) of the genes: ABCA1 
(****p < 0.0001), ABCG1 (p = 0.17), SR-A1 (p = 0.55) and SR-B1 (p = 0.32) involved in reverse cholesterol 
transport from peripheral cells, using Mann-Whitney test between groups. Results given as mean with 95% CI. 
mRNA levels were quantified by qPCR and values given in relation to the reference genes β-actin and GAPDH.
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systemic immune activation and non-infectious complications in CVID, expanding the role of HDL as an impor-
tant modulator of inflammation.
One study has previously shown reduced HDL cholesterol and Apo A-1 levels in 18 patients with CVID and 
six patients with X-linked agammaglobulinaemia compared to 12 healthy controls, with a negative correlation 
between plasma levels of HDL and TNF in these patients23. Herein we extend these findings by showing decreased 
HDL cholesterol levels in a substantially larger study population, and further demonstrate that the reduced HDL 
cholesterol levels are stable during temporal testing. Importantly, the lowest HDL levels were seen in CVID 
patients with autoimmune and inflammatory complications. This suggests that low HDL levels are related to 
sterile inflammation rather than infectious-driven inflammation, supported by the detection of sCD25, a robust 
marker of T cell activation, as the strongest predictor for low HDL levels. In line with our findings, previous 
studies have found low HDL levels associated with disease activity and systemic inflammation in autoimmune 
diseases such as inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus and Sjogren’s 
syndrome24–27.
The detailed study of HDL particle composition gave some discordant results showing normal proportions 
of the small HDL particles but decreased levels of Apo A-1 in CVID, both particles of major importance to HDL 
function. However, our studies using control and patient serum to reflect HDL acceptor capacity for cholesterol 
in RCT showed significantly impaired HDL function in CVID, primarily reflecting impaired cholesterol acceptor 
Figure 6. Cholesterol efflux from CVID and control macrophages to universal serum. Cholesterol efflux 
from monocyte-derived macrophages from CVID patients with non-infectious complications and age- and 
sex matched healthy controls to universal serum. Results given with bars for median and interquartile range, 
*p < 0.05 using Wilcoxon matched pair signed rank test.
Figure 7. ATF3 mRNA levels and HDL cholesterol effects on TLR2-stimulated TNF release from mononuclear 
cells in CVID patients and controls. (a) ATF3 mRNA expression in CVID patients and healthy controls; results 
given with bars for median and interquartile range, ****p < 0.0001 using Mann-Whitney test between groups. 
mRNA levels were quantified by qPCR and values given in relation to the reference genes β-actin and GAPDH. 
(b) Effect of increasing HDL cholesterol concentration on TLR2- (Pam3Cys) stimulated TNF release from 
mononuclear cells in CVID (n = 6) and controls (n = 6); *p < 0.05. Results illustrated as median with variance, 
p-values calculated using repeated measures ANOVA analysis. The difference between CVID patients and the 
control group in TNF release at baseline from mononuclear cells after Pam3Cys stimulation was found non-
significant (p = 0.389) when performing Student’s t-test on log-transformed datasets.
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capacity in CVID patients with non-infectious complications. The consequence of this impaired HDL acceptor 
function was augmented by decreased cholesterol efflux from macrophages in CVID patients, likely related to 
decreased expression of the ATP-binding cassette transporter ABCA1.
A major finding in the present study was the association between decreased levels and function of HDL and 
systemic inflammation. These correlations could also be supported by functional studies. The combined impair-
ment of cholesterol acceptor function in serum and reduced reverse cholesterol transport from macrophages 
likely leads to lipid accumulation in these cells. A similar pattern in dendritic cells has been demonstrated to 
promote a TLR mediated inflammatory response28. Additionally, we found that PBMC from CVID patients had 
lower expression of transcription factor ATF3 mRNA along with a modestly attenuated anti-inflammatory effect 
of HDL as assessed by TNF release in TLR2 activated PBMC. ATF3 has been found to be vital in the protective 
effect of HDL against TLR induced inflammation17. Increased TNF levels are typical of the inflammatory CVID 
phenotype8, and our findings could relate this phenotype to impaired cellular HDL responses.
A rational line of reasoning could suggest the chronic systemic inflammation found in CVID patients would 
lead to increased incidence of cardiovascular disease in this group. However, no clear evidence has been found 
to substantiate this hypothesis29. American and European registry data have rather identified lung disease and 
autoimmune manifestations as the most prevalent complications to CVID7,30. It has however been speculated that 
atherosclerosis is present but does not amount to clinical levels substantial enough to cause cardiovascular disease 
due to the reduced life expectancy in CVID patients with non-infectious complications29.
The reasons for the decreased HDL levels and function in CVID patients are, at present, not clear. We have 
previously shown GI tract inflammation in a large proportion of CVID patients31 which could influence lipid 
metabolism. Patients with CVID enteropathy have been found to have low mucosal IgA levels in the duode-
num, which has been suggested could shift intestinal molecular pathways from appropriate lipid metabolism 
to enteropathy-inducing immune processes32. The gut microbiota has previously been shown to contribute to 
variation in blood lipids33 and alteration of the gut microbiota composition in CVID has been linked to systemic 
inflammation34. Importantly, whereas inflammation per se could have contributed to the decreased HDL levels35, 
decreased HDL levels may further increase inflammation in CVID patients, hence representing a pathogenic 
loop. In a clinical setting, such a loop could be targeted therapeutically by Apo A-1 mimetics36, cholesteryl trans-
fer protein (CETP)-inhibitors37, statins or a combination thereof.
Based on the prevalence of CVID, the total number of patients in the cholesterol analysis part of the study was 
large and the study included robust characteristics of HDL composition and function, viewed as a major strength 
of this study. Still there are some limitations, including a rather low number of patients in some of the functional 
sub-studies. Furthermore, the blood samples were not obtained at a fasted state. We do however suggest that this 
should only have minor influences on the HDL data. Finally, we lack protein data on some important molecules 
like ABCA1 and ATF3, which could have been useful as mRNA may not necessarily reflect the protein expression 
of these molecules.
In conclusion, the present study shows novel data demonstrating marked disturbances in HDL cholesterol 
levels and HDL function in CVID, with HDL levels inversely correlating with inflammatory markers and a more 
severe phenotype in these patients. Furthermore, it shows reduced HDL function via impaired reverse cholesterol 
transport in CVID patients, which appears to be an important factor contributing to their systemic inflammation 
and autoimmune and inflammatory manifestations. The identification of HDL function as a target for treat-
ment to reduce inflammatory and autoimmune complications in CVID should be further explored. Our findings 
support a link between a dysregulated immune system, lipid metabolism, inflammation and autoimmunity in 
humans. Indeed, the findings of this study could be transferable and therapeutically useful to other and more 
common inflammatory and autoimmune diseases.
Methods
study population. CVID patients were recruited from the outpatient clinic at the Section of Clinical 
Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, which functions as a national 
center for diagnosis and treatment of adults with primary immunodeficiency diseases in Norway. CVID was 
defined as decreased serum levels of IgG, IgA and/or IgM by a minimum of two standard deviations below the 
mean for age, whilst excluding other causes of hypogammaglobulinemia. Patients with ongoing acute infec-
tions and patients using immunosuppressive drugs were excluded, whereas use of statins was not an exclusion 
criterion. The larger cohort of 102 CVID patients was recruited from November 2011 to December 2012 and 
the smaller cohort of 40 CVID patients was recruited between October 2013 and October 2014 as previously 
described34,38 (Supplemental Fig. S4). For comparison, we included 30 healthy controls based on disease history 
and on no regular medications. Blood was drawn for PBMC isolation, serum and plasma samples from all con-
trols. However, technical issues with the plasma samples from two healthy controls lead to a reduced number 
of controls (n = 28) for the plasma analyses. Supplemental Table S3 gives a detailed overview of which CVID 
patients contributed to the different functional studies and which were also part of the large and small cohorts. 
For cellular studies on macrophage cholesterol efflux and the effect of HDL on TLR-stimulated release of TNF 
and IL-6 from macrophages, we specifically wanted to focus on the possible pathological mechanisms in patients 
with systemic inflammation and autoimmunity and therefore selected CVID patients with known non-infectious 
complications for these particular analyses.
Blood sampling. Plasma for lipid analyses was sampled into EDTA collection tubes, immediately immersed 
in melting ice and centrifuged within 30 minutes at 2,500 g for 20 minutes prior to being stored at −80 °C until 
analysis. For patients on intravenous Ig therapy, blood samples were collected just prior to infusion.
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Analyses of lipid and inflammatory parameters. Total cholesterol, HDL cholesterol, Apo A-1 and low 
density lipoprotein (LDL) cholesterol were measured enzymatically on a Hitachi 917 system (Roche Diagnosis 
GmbH, Mannheim, Germany) using the cholesterol (cholesterol CHOD-PAP), HDL-cholesterol plus (catalog 
no. 04713257190) and LDL-cholesterol plus (catalog no. 04714423190) kits from Roche Diagnostics. CRP lev-
els were analysed via the routine hospital laboratory on the day of sampling using a high-sensitivity method. 
Plasma levels of sCD14 and sCD25 were quantified in duplicate by enzyme immunoassays obtained from R&D 
Systems (Minneapolis, MN). Endotoxin was analysed by Limulus Amebocyte Lysate chromogenic assay (Lonza, 
Walkersville, MD) according to the manufacturer’s instructions, with the following modifications: samples were 
diluted 10-fold to avoid interference with background colour and preheated to 68 °C for 10 minutes prior to analy-
sis to dissolve immune complexes. Supernatant TNF and IL-6 levels were analyzed with a V-plex Proinflammatory 
Panel 1 kit from Meso Scale Discovery (Meso Scale Diagnostics, LLC, 1601 Research Blvd. Rockville, MD) using 
QuickPlex SQ120.
Characterizing HDL sub-fractions. EDTA plasma samples were quantified using a commercial 
high-throughput proton NMR metabolomics platform (Nightingale Health Ltd, Helsinki, Finland). Details of 
the experimentation and applications of the NMR metabolomics platform have previously been described39. The 
mean size for the HDL particles was calculated by weighting the corresponding subclass diameters with their 
particle concentrations, and the four HDL subclass sizes were defined as 14.3 nm (XL), 12.1 nm (L), 10.9 nm (M), 
and 8.7 nm (S).
Isolation of PBMC. Peripheral blood mononuclear cells (PBMC) were isolated from heparinised venous 
blood by gradient centrifugation using Lymphoprep (Axis Shield, Oslo, Norway) within 1 hour after blood col-
lection. PBMC were used for further in vitro experiments immediately following isolation or stored as pellet in 
−80 °C for PCR analyses.
Quantitative real-time (RT)-PCR analyses. Total RNA was isolated from PBMC using RNeasy spin 
columns as described by the manufacturer (Qiagen, Hilden, Germany). Isolated RNA was treated with DNase 
(Qiagen) and stored at −80 °C for later analysis. RNA concentrations and purity were assessed by spectropho-
tometer absorbance (NanoDrop ND-1000 Thermo Scientific, Wilmington, DE). 500 ng of RNA was loaded into 
the cDNA synthesis using q-Script cDNA Synthesis kit (Quanta Bioscience, Gaithersburg, MD). Quantification 
of mRNA was performed using Perfecta SYBR Green qPCR Fast Mastermix (Quanta Bioscience) on the 7900HT 
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) with the accompanying software SDS 2.4. All 
primer sequences can be provided upon request. As small volumes were used in the analyses of human samples, 
robot pipetting for RT-qPCR reactions was employed. For each transcript, RT-qPCR was conducted in duplicate. 
Target transcript levels were quantified by the comparative Ct method using the average Ct-median value from 
reference genes β-actin and GAPDH as endogenous control.
Functional studies. Serum as cholesterol acceptor. The human monocytic cell line THP-1 monocytes 
(ATCC, Chicago, IL) were differentiated to THP-1 macrophages using 12-myristate 13-acetate (PMA, Sigma) 
(100 nM). After 24 hours the macrophages were loaded with 14C-cholesterol (0.5 µCi/ml [18.5 mBq/l] American 
Radiolabel Chemicals, Saint Louis, MO) in regular growth medium added oxidized LDL (10 µg/ml) and further 
grown for 48 hours. After overnight incubation in sterile 0.2% (wt/v) human serum albumin in RPMI1640, the 
cholesterol acceptor capacity was measured adding 2.5% (v/v) heat-inactivated serum (in RPMI-1640 medium) 
from CVID patients and healthy controls to the lipid laden THP-1 macrophages. After 3 hours incubation, 
the medium was collected and 14C-cholesterol measured by liquid scintillation counter (TRI-CARB 2300 TR 
Scintillation Counter [Packard, Waltham, MA]). Total cell-associated 14C-cholesterol loading of THP-1 mac-
rophages was assessed in a parallel set up. Percentage efflux was calculated using the equation: [DPMmedium/(DPM 
(cell+medium))] × 100.
Cholesterol efflux capacity. Cell viability in the PBMC suspensions was tested using CountessTM automated cell 
counter, before seeding onto a 24-well plate (NunclonTM Delta Surface, Thermo Fisher scientific, MA). The cells 
were incubated for an hour, washed twice, and plastic adhered monocytes were further stimulated with TNF 
10 ng/ml (R&D Systems) for the mononuclear cells to differentiate into a macrophage-like phenotype. After two 
days, the macrophage-like cells were loaded with 14C-cholesterol (0.5 µCi/ml [18.5 mBq/l]) in regular growth 
medium added oxidized LDL (10 µg/ml). After 48 hours lipid loading, the cells were incubated overnight with 
0.2% (wt/v) human serum albumin in RPMI1640. The patient and control cells’ efflux capacity were assessed 
using 2.5% heat inactivated serum from one healthy individual as detailed above.
ATF3 and anti-inflammatory reprogramming. PBMC were isolated as described above. The cells were pre-treated 
for 6 hours with HDL (0.5 mg/ml, 2 mg/ml and no HDL, respectively [purified human HDL, Kalen Biomedical, 
LLC, Germantown, MD]). They were then stimulated overnight with the TLR4 ligand LPS from Escherichia coli 
026:B6 (2.5 ng/ml) and TLR2 ligand Pam3Cys (0.8 µg/ml), before supernatant levels of TNF and IL-6 were meas-
ured as described above.
Statistics. The datasets for HDL analyses, including HDL subclasses, were not normally distributed as per 
Kolmogorov-Smirnov normality tests and the data was therefore log transformed. Where normal distribution 
was achieved, we continued with two-tailed multivariate testing. Where normal distribution was not achieved, we 
applied Mann-Whitney non-parametric testing, all tests with significance level 0.05. We ran bivariate correlation 
analyses in addition to forced and stepwise linear regression analyses to investigate the connections between lipid 
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levels and inflammatory markers. For the longitudinal data, we compared two different time points using related 
samples Wilcoxon signed rank test. For the functional studies with age and sex matched controls we applied 
matched pair Wilcoxon signed rank test, and where repeated measurements were done under various HDL con-
centrations we used repeated measures ANOVA analysis.
study approval. The study was approved by the Regional Committee for Medical and Health Research 
Ethics of South-Eastern Norway (number 2012/521, 2013/1037) and conducted in accordance with the Helsinki 
Declaration. All participants provided written, informed consent. The study participants were given a study num-
ber which was used for handling samples and analyses throughout the study.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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